Patterns and outcomes in HR+/HER2- advanced/metastatic breast cancer patients in Brazil receiving palbociclib.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-01-01 Epub Date: 2024-09-05 DOI:10.1080/14796694.2024.2388022

Patricia Simon, Ankita Jain, Alexandra Guarin, Luciana Piton, Carla Fabrine Carvalho, Júlia Lima, Felipe Nazareth

{"title":"Patterns and outcomes in HR+/HER2- advanced/metastatic breast cancer patients in Brazil receiving palbociclib.","authors":"Patricia Simon, Ankita Jain, Alexandra Guarin, Luciana Piton, Carla Fabrine Carvalho, Júlia Lima, Felipe Nazareth","doi":"10.1080/14796694.2024.2388022","DOIUrl":null,"url":null,"abstract":"Aim: To outline the demographic and clinical features, treatment approaches and clinical outcomes of patients treated with palbociclib as the initial therapy for HR+/HER2- advanced or metastatic breast cancer (aBC/mBC) in private healthcare facilities in Brazil.Materials & methods: This study involved a retrospective review conducted from June 2022 to May 2023.Results: The study included 121 patients, with an average age of 54.4 years, and 82 (67.7%) were menopausal at the time of diagnosis. Of these, 51 patients (42.1%) were treated with palbociclib and fulvestrant, while 67 patients (55.8%) received palbociclib and aromatase inhibitors. Most patients (65.3%) did not need to adjust their doses. The progression-free survival rates were 78% at 6 months and 60% at 12 months. Overall survival rates were 86% at 6 months and 70% at 12 months.Conclusion: Palbociclib combinations show promising effectiveness in managing HR+/HER2- advanced or metastatic breast cancer.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534102/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2388022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To outline the demographic and clinical features, treatment approaches and clinical outcomes of patients treated with palbociclib as the initial therapy for HR+/HER2- advanced or metastatic breast cancer (aBC/mBC) in private healthcare facilities in Brazil.Materials & methods: This study involved a retrospective review conducted from June 2022 to May 2023.Results: The study included 121 patients, with an average age of 54.4 years, and 82 (67.7%) were menopausal at the time of diagnosis. Of these, 51 patients (42.1%) were treated with palbociclib and fulvestrant, while 67 patients (55.8%) received palbociclib and aromatase inhibitors. Most patients (65.3%) did not need to adjust their doses. The progression-free survival rates were 78% at 6 months and 60% at 12 months. Overall survival rates were 86% at 6 months and 70% at 12 months.Conclusion: Palbociclib combinations show promising effectiveness in managing HR+/HER2- advanced or metastatic breast cancer.

查看原文本刊更多论文

巴西接受帕博西尼治疗的HR+/HER2-晚期/转移性乳腺癌患者的模式和疗效。

目的：概述在巴西私立医疗机构接受帕博西尼（palbociclib）作为HR+/HER2-晚期或转移性乳腺癌（aBC/mBC）初始疗法的患者的人口统计学特征、临床特征、治疗方法和临床结果。材料与方法：本研究对 2022 年 6 月至 2023 年 5 月期间的情况进行了回顾性分析。研究结果研究共纳入 121 名患者，平均年龄为 54.4 岁，其中 82 人（67.7%）在确诊时已绝经。其中，51名患者（42.1%）接受了palbociclib和氟维司群治疗，67名患者（55.8%）接受了palbociclib和芳香化酶抑制剂治疗。大多数患者（65.3%）无需调整剂量。6个月和12个月的无进展生存率分别为78%和60%。6个月和12个月的总生存率分别为86%和70%。结论帕博西尼（Palbociclib）联合用药在治疗HR+/HER2-晚期或转移性乳腺癌方面显示出良好的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.